Title:
NOVEL DEUTERATED TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION THEREOF AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/155337
Kind Code:
A1
Abstract:
Disclosed is a deuterated triazine compound represented by formula I or a pharmaceutically acceptable salt, isomer, prodrug or cocrystal thereof. Also disclosed are a preparation method for the deuterated compound, a composition of the deuterated compound and use of the deuterated compound. The compound, as a 3CL protease inhibitor, on the basis of having similar inhibitory activity against viruses, achieves better pharmacokinetic properties and therapeutic effects and better druggability. The structural formula of formula I is shown on the left.
Inventors:
HUANG CAIGU (CN)
SUN HUI (CN)
ZENG WEILIN (CN)
SUN HUI (CN)
ZENG WEILIN (CN)
Application Number:
PCT/CN2022/097499
Publication Date:
August 24, 2023
Filing Date:
June 08, 2022
Export Citation:
Assignee:
GUANGZHOU ANOVENT PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D403/14; A61K31/53; A61P31/12; A61P31/14
Domestic Patent References:
| WO2022035911A2 | 2022-02-17 |
Foreign References:
| CN114539228A | 2022-05-27 | |||
| CN114507221A | 2022-05-17 |
Other References:
UNOH YUTO, UEHARA SHOTA, NAKAHARA KENJI, NOBORI HARUAKI, YAMATSU YUKIKO, YAMAMOTO SHIHO, MARUYAMA YUKI, TAODA YOSHIYUKI, KASAMATSU: "Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", BIORXIV, 26 January 2022 (2022-01-26), XP093086254, [retrieved on 20230927], DOI: 10.1101/2022.01.26.477782
WANG XI, DU YUNFE: "Research Progress on Deuterated Drugs", TIANJIN PHARMACY, CHINA, vol. 32, no. 1, 26 August 2020 (2020-08-26), China , pages 44 - 56, XP055933229, ISSN: 1006-5687
WANG XI, DU YUNFE: "Research Progress on Deuterated Drugs", TIANJIN PHARMACY, CHINA, vol. 32, no. 1, 26 August 2020 (2020-08-26), China , pages 44 - 56, XP055933229, ISSN: 1006-5687
Download PDF: